Clinical Trial

Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 10, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to compare 28-day mortality among patients with carbapenem resistant A. baumannii infections in two hypothetical target trials where patients receive 7 days of a cefiderocol-based treatment strategy or 7 days of a best available therapy treatment strategy.
Trial Details
NCT Number NCT07226557
Lead Sponsor National Institutes of Health Clinical Center (CC)
Conditions Carbapenem Resistant Bacterial Infection, Acinetobacter Baumannii Infection, Antimicrobial Drug Resistance
Enrollment 5,000 participants
Start Date 2025-01-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-10